Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 90162, held by Unichem Labs Ltd. Topiramate.
As of Nov 15, 2026, ANDA 90162 (Topiramate), held by Unichem Labs Ltd, was first approved by FDA on Mar 27, 2009, with 16 approved supplements and 0 published complete response letters.
Topiramate tablets are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate tablets are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2009 | Original application | Approved | None posted |
| Topiramate25MG · tablet;oral | Topiramate | Rx |
| Topiramate50MG · tablet;oral | Topiramate | Rx |
| Topiramate100MG · tablet;oral | Topiramate | Rx |
| Topiramate200MG · tablet;oral | Topiramate | Rx |
| Sep 17, 2026 | Supplement 34Labeling · Standard review | Approved | None posted |
| Sep 17, 2026 | Supplement 32Labeling · Standard review | Approved | None posted |
| Sep 22, 2023 | Supplement 31Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 30Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 27Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 25Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 20Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 18Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 1, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 19, 2013 | Supplement 2Manufacturing | Approved | None posted |
| Dec 28, 2010 | Supplement 1Labeling | Approved | None posted |
| Mar 27, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters